Showing results (51-60 of 422) with videos related to
Sort By:
Pageof 43
STAR Protocols|August 1, 2024
Isolation, expansion, and adoptive transfer of human ILC2s for the treatment of mice bearing liquid and solid tumorsZhenlong Li, Rui Ma, Hejun Tang, et al.Trends in Immunology|May 21, 2025
YTHDF2: a key RNA reader and antitumor targetSai Xiao, Songqi Duan, Michael A Caligiuri, et al.Hematology. American Society of Hematology. Education Program|November 25, 2004
Immunotherapeutic approaches for hematologic malignanciesMichael A Caligiuri, Andrea Velardi, David A Scheinberg, et al.Plos Biology|April 28, 2018
Dependence of innate lymphoid cell 1 development on NKp46Yufeng Wang, Wenjuan Dong, Yibo Zhang, et al.Haematologica|March 24, 2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485Alice S Mims, Anjali Mishra, Shelley Orwick, et al.Cardio-Oncology (London, England)|October 23, 2021
Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemiaLisa Kim, Brian Fowler, Courtney M Campbell, et al.Oncoimmunology|June 5, 2013
Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapyChristopher A Alvarez-Breckenridge, Jianhua Yu, Michael A Caligiuri, et al.Cell Stem Cell|January 9, 2026
Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapyZahir Shah, Lei Tian, Michael A Caligiuri, et al.Immunity|November 23, 2017
The Broad Spectrum of Human Natural Killer Cell DiversityAharon G Freud, Bethany L Mundy-Bosse, Jianhua Yu, et al.International Journal of Hematology|August 5, 2003
Biology and clinical impact of human natural killer cellsSherif S Farag, Jeffrey B VanDeusen, Todd A Fehniger, et al.Pageof 43